Larimar Therapeutics, Inc. (LRMR)
D
Pipeline Grade
Financial Position (from SEC Filings)
$177.9M
Cash & Equivalents
$44.6M
Quarterly Burn Rate
12 mo
Est. Cash Runway
$445M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-01-01 | Phase2 Readout | — |
Active Clinical Trials (1)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06447025 | An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia | PHASE2 | Recruiting | 85 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-29 | 8-K | Larimar Therapeutics, Inc. (LRMR) (CIK 0001374690) - EX-99.2 | EDGAR |